Status:
COMPLETED
Double-Blind Naltrexone in Kleptomania
Lead Sponsor:
University of Minnesota
Conditions:
Kleptomania
Eligibility:
All Genders
21-75 years
Phase:
PHASE2
Brief Summary
The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.
Detailed Description
The proposed study will consist of 8 weeks of treatment with either naltrexone or placebo in 20 subjects with kleptomania. The hypothesis to be tested is that naltrexone will be effective in reducing ...
Eligibility Criteria
Inclusion
- men and women age 21-75
- current DSM-IV kleptomania.
Exclusion
- unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination
- history of seizures
- myocardial infarction within 6 months
- current pregnancy or lactation, or inadequate contraception in women of childbearing potential
- clinically significant suicidality
- current or recent (past 3 months) DSM-IV substance abuse or dependence
- illegal substance within 2 weeks of study initiation
- initiation of psychotherapy or behavior therapy from a mental health professional for the treatment of kleptomania within 3 months prior to study baseline
- initiation of a psychotropic medication within 2 months prior to study inclusion
- previous treatment with naltrexone
- treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00332579
Start Date
May 1 2006
End Date
September 1 2008
Last Update
July 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55454